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CROSSLINKED HYALURONAN GEL (HYLASTAN): CLEARANCE FOLLOWING
A SINGLE INTRA-ARTICULAR INJECTION IN RABBITS AND
BIOCOMPATIBILITY ACCORDING TO ISO 10993
P. Konowicz1, L. Avila1, L.-P. Yu2, E. Voschin2, K. Skinner2, R. Miller1,
C. O’Brien3, R. Corazzini2, E. Skrabut1
1Genzyme Corp., Waltham, MA; 2Genzyme Corp., Framingham, MA; 3Genzyme
Corp., Cambridge, MA
Purpose: Clearance and biocompatibility studies were conducted on radi-
olabeled and unlabeled crosslinked hylastan gels, respectively. This study
objective was to determine the temporal distribution and concentration of
14C-labeled gel in rabbit hindlimbs following a single intra-articular injec-
tion. Biocompatibility testing of the unlabeled gel was conducted according
to standard ISO 10993 methods to determine safety of the medical device.
Methods: Hylastan gels were prepared by crosslinking high molecular
weight HA at an initial polymer concentration of 5.25% using 0.035 Meq of
unlabeled or 14C-labeled divinyl sulfone. The gels were washed with acid
and saline then swollen in phosphate buffered saline (pH 7.5) to a concen-
tration of 9.1 mg/mL. In the clearance study, a total of 12 male New Zealand
White rabbits, approximately three months of age with a body weight of
1.8 to 2.3 kg, were given a single intra-articular injection of 14C-labeled
gel (0.1 μCi/animal) into both hindlimbs. Two animals were euthanized at
1 hour and 7, 28, 56, 84 and 85 days post-dose. Following sacriﬁce, each
carcass was deep frozen. The left hindlimbs were removed and solubilized
in-toto and radioactivity determined by liquid scintillation spectroscopy.
The right hindlimbs were removed and embedded in carboxymethylcellu-
lose and frozen. Each block was sectioned serially at a 30 μm thickness
and freeze-dried for quantiﬁcation. Radioactivity distribution in tissues was
determined by quantitative whole body autoradioluminography (QWBA).
Biocompatibility testing with non-radiolabeled gel was performed in ac-
cordance with ISO 10993 guidelines for bone and tissue contacting medical
devices. All the testing was conducted pursuant to GLP 21 CFR 58. All
non-clinical animal studies were reviewed and approved by IACUC.
Results: Following intra-articular administration of 14C-labeled gel, any
clinical signs observed throughout the study were considered to be
incidental. The highest mean radioactivity concentration values were
observed in the saccus (5218 μg eq/g) and the fat pad (798 μg eq/g) at
1 hour post-dose. Moderate levels of radioactivity were also seen in the
lymph node (popliteal) at 7 days post-dose and meniscus (medial) at 1 hour
post-dose. The mean limit of quantiﬁcation for tissues analyzed by QWBA
generally ranged from 21.6 to 27.3 μg eq/g with the exception of the 56 day
timepoint where the mean limit of quantiﬁcation was 1213 μg eq/g. The left
hindlimb which included the bone marrow (femur and tibia), condyle of the
femur (distal) and condyle of the tibia (proximal) and patella had concen-
tration values that were below the limit of quantiﬁcation at all timepoints.
Although radioactivity could still be detected in images from animals up
to the 56 day timepoint, radioactivity concentrations were below the limits
of quantiﬁcation for all tissues of interest by 28 days post-injection.
The calculated half-life of the gel was 6.23 days. Overall, the mean content
of radioactivity in the left hindlimbs was 99.6% at 1 hour post-injection,
45.9% at 7 days post-injection and below the limit of quantiﬁcation for
subsequent timepoints. Therefore, most of the radioactivity administered
was eliminated by 28 days post-injection. The limit of quantiﬁcation for
the hindlimbs was approximately 8% of the administered dose.
Biocompatibility testing showed the unlabeled hylastan gel to be non-
cytotoxic, non-sensitizing, non-mutagenic, slightly reactive (short and long
term implantation), a negligible irritant (intradermal), non-toxic (acute
systemic) and non- pyrogenic.
Conclusions: Following a single intra-articular injection of 14C-hylastan gel,
the test material cleared from the joint space with a half-life of 6.23 days.
There were no adverse events related to the administration of the gel. The
battery of biocompatibility testing on the crosslinked hylastan gel showed
that the material was safe.
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AN EX VIVOMODEL FOR DEGENERATIVE CARTILAGE DISEASE
E. Landman1, R. Miclea2, C. van Blitterswijk1, M. Karperien1
1Univ. of Twente, Enschede, Netherlands; 2Leiden Univ. Med. Ctr., Leiden,
Netherlands
Purpose: In osteoarthritis (OA), the breakdown of extracellular matrix
components exceeds the synthesis of new matrix, which results in the
degeneration of cartilage. In the search for new therapeutics for OA, we aim
screening of libraries to identify small molecules that either stimulate the
synthesis of new cartilage matrix, or inhibit the degradation of the matrix.
For this purpose we have developed an ex vivo model for osteoarthritis
using mouse fetal metatarsals. To mimic an osteoarthritic environment,
we treat the metatarsals with TNFα or IL1β or a combination of the two
cytokines.
Methods: Mouse fetal metatarsals were isolated at day 17 of gestation, and
cultured for 2 days prior to addition of TNFα and IL1β. The metatarsals
were treated with TNFα, IL1β or a combination for 7 days and metatarsals
were examined morphologically before harvesting for histological analysis.
Results: Morphological analysis of the metatarsals after treatment with
TNFα and IL1β for 7 days showed no signiﬁcant changes in the size of
the metatarsals. In marked contrast, treatment with a combination of
both TNFα and IL1β causes severe degradation of the cartilage. Histological
examination of the metatarsals showed a decrease in Alcian Blue and
Safranin O staining after treatment with both TNFα and IL1β, indicating
a loss of glycosaminoglycans in the matrix. Glycosaminoglycan content
of the extracellular matrix was quantiﬁed. Treatment with TNFα reduced
glycosaminoglycan content with 60%, IL1β with 90% and the combination
of both with almost 100%.
Conclusions: Based on the results of these experiments, it can be con-
cluded that treatment with either TNFα, IL1β or both can cause cartilage
degeneration in mouse fetal metatarsals, resulting in an osteoarthritis-like
situation. We will use this model to screen libraries of small molecules
to identify new therapeutics for treatment of degenerative cartilage dis-
ease.
Biomarkers
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INFLAMMASOME ACTIVATION IN OSTEOARTHRITIS BY URIC ACID
T.V. Stabler, A.E. Heinrichs, K.M. Huffman, G.E. McDaniel, V.B. Kraus
Duke Univ. Med. Ctr., Durham, NC
Purpose: The production of mature active IL-18 and IL-1β requires inﬂam-
masome activation. One mechanism for the production of inﬂammasomes
is the activation of the NOD-like receptor protein NALP3 by uric acid
(UA). We sought to determine whether in persons with osteoarthritis (OA)
elevated synovial ﬂuid (SF) UA might be associated with elevated levels of
IL-18 and IL-1β, indicative of inﬂammasome activation and OA severity.
Methods: Patients: A total of 159 participants (118 female, 41 male)
were enrolled in the NIH sponsored Strategies to Predict Osteoarthritis
Progression (POP) study with 138 returning for 3 year follow-up. The study
was approved by the Duke Univ. IRB with informed consent being obtained
from all subjects. Participants met radiographic criteria and ACR criteria for
symptomatic OA of at least one knee with a Kellgren-Lawrence (KL) grade
of 1-4.
Radiographic Imaging: Posteroanterior ﬁxed-ﬂexion knee radiographs were
obtained and read for KL grade and individual radiographic features of OA,
including joint space narrowing (JSN) and osteophyte (OST)
Scintigraphic Imaging: Scintigraphic images of the knee were obtained at 2.5
hours (late phase) after injection of technetium-99m methylene diphos-
phonate. The intensity of bone uptake was scored for each compartment
(medial and lateral) of the tibiofemoral knee joint.
SF analysis: UA was analyzed using HPLC. Cytokines were quantiﬁed us-
ing the MBL Human IL-18 ELISA and the Quantikine Human IL-1β High
Sensitivity ELISA kits, both from R&D Systems (Minneapolis, MN).
Pain Scores: Knee symptoms were ascertained by the NHANES I criterion of
pain, aching or stiffness on most days of any one month in the last year.
Statistical Analysis: Descriptive statistics and univariate analyses were per-
formed using Graphpad Prism software (San Diego, CA). Relationships
between SF analytes and between SF analytes and OA were analyzed using
the GenMOD procedure, to control for within subject correlation of knee
data, with addition of a repeated statement (GLM, SAS Enterprise Guide,
Cary, NC).
Results: The synovial ﬂuid analyses were limited to 69 study participants
(49 women and 20 men) with suﬃcient synovial ﬂuid volumes for uric
acid analyses. The mean (±SD) age of this subset was 64.5±10.1 years
(68.9±7.17 years for men, and 62.7±10.6 years for women). The mean
(±SD) body mass index was 32.4±7.1 kg/m2 and similar between the sexes.
Knee OA ranged from 1-4 in severity (23.1%, 14.6%, 49.2%,13.1% for each
